healthcare
Golden Equator, KIP launch Southeast Asia tech fund
Singapore’s Golden Equator Capital and Korea Investment Partners (KIP) have jointly launched a S$120 million ($88 million) Southeast Asia technology fund focused on start-ups and small to medium-sized enterprises (SME).
Malaysia's Sunway launches $50m VC fund
Sunway, a Malaysian conglomerate with operations in real estate and construction, has launched a venture capital fund with a view to raising $50 million.
China's Genesis targets $600m for second fund
Genesis Capital, a Chinese venture capital firm established by Richard Peng, formerly head of M&A at Tencent Holdings, is targeting $600 million for its second fund.
EQT closes Asia mid-market fund at $800m
EQT Partners has closed its Asia-focused middle market private equity fund on target with $800 million in commitments.
China's Decheng targets $450m for third fund
Chinese healthcare and life sciences-focused GP Decheng Capital is targeting $450 million for its third US dollar-denominated fund.
China VC specialization to accelerate as ecosystem expands
China’s venture capital ecosystem is set to see a rapid proliferation of niche sector funds as overall economic growth piques domestic competition in the asset class.
China’s Qiming raises $1.39b across three VC funds
Qiming Venture Partners has closed two China-focused VC funds – including its sixth US dollar-denominated vehicle and fifth renminbi-denominated vehicle – and a newly-established US healthcare fund, with $1.39 billion in aggregate commitments.
CLSA backs MBO of Japan medical IT systems supplier
CLSA Capital Partners (CLSA CP) has supported a management buyout of NHOSA Corporation, which provides electronic health record (EHR) systems to dental clinics across Japan.
VCs invest $12m in US, Southeast Asia-based Element
A number of Asian VCs including MDI Ventures, a unit of Telkom Indonesia, have joined a $12 million Series A round for Element, a biometrics technology developer based in New York, Jakarta, and Singapore.
Chinese biotech firm Biocytogen raises $65m
Biocytogen, a Chinese contract research organization (CRO) that provides genetically engineered mice for drug testing, has raised RMB410 million ($65 million) in a Series C round of funding led by CMB International Capital, an investment arm of China...
Tencent leads $80m round for China’s Miaoshou Doctor
Tencent Holdings has led a RMB500 million ($80 million) Series C round for Miaoshou Doctor, a China-based healthcare services provider.
Q&A: IMM Private Equity’s Joseph Lee
IMM Private Equity’s Joseph Lee discusses the new sectors taking focus away from Korea’s traditional manufacturers, along with the potential for tender offers, IPOs and secondary sales in the market
VCs in $47m round for Chinese AI medical imaging firm
Beijing Infervision, a Chinese company that develops medical imaging technology empowered by artificial intelligence (AI), has raised RMB300 million ($47 million) in funding from investors including Xianghe Capital.
Samena, Cenova in $83m round for Hong Kong’s Virtus Medical
Virtus Medical Holdings, a Hong Kong-based private medical services provider, has raised an $83 million round of funding from Samena Capital and Cenova Capital.
Yunfeng, MicroPort agree international medical devices carve-out
Chinese PE firm Yunfeng Capital and Hong Kong-listed medical device manufacturer MicroPort Scientific Corporation will acquire US-listed LivaNova's cardiac rhythm management (CRM) business for $190 million in cash.
Hony-backed healthcare platform acquires TCM hospital
Hospital Corporation of China (HCC), a buyout platform established by Hony Capital, has acquired a 70% stake in Jiande Hexu Enterprise Management, owner of a traditional Chinese medicine (TCM) hospital and other healthcare businesses, for RMB483 million...
China’s 6 Dimensions raises $844m for debut healthcare fund
China’s 6 Dimensions Capital, which was formed through the merger of WuXi Healthcare Ventures and Frontline BioVentures, has raised approximately $844 million for its debut healthcare fund.
SDIC, AstraZeneca agree China pharma JV
SDIC Fund Management, a GP under China’s State Development & Investment Corporation (SDIC), and AstraZeneca have formed a China-based joint venture that will develop and commercialize new medicines.
China cancer treatment developer receives $101m
China Venture Capital Fund, a VC vehicle backed by the Chinese government, and ChinaEquity Group have jointly led a RMB670 million ($101 million) round for 3D Medicines, which focuses on personalized diagnostics and treatment for cancer.
Australia backs four healthcare tech start-ups in VC push
The CSIRO Innovation Fund, a venture program under the Australian government’s latest science development policy push, has invested in its first four local technology start-ups.
China's HighLight Capital closes Fund II at $250m
Chinese healthcare-focused GP HighLight Capital, which was set up by former CDH Investments executive Steven Wang, has closed its second US dollar-denominated fund at the hard cap of $250 million.
Japan's NSSK closes Fund II at $530m
Japanese private equity firm NSSK has closed its second fund oversubscribed with JPY60 billion ($531 million) in commitments.
ADB re-ups in OrbiMed's Asia healthcare fund
The Asian Development Bank (ADB) has invested $60 million in OrbiMed Asia Partners III, the third Asian private equity fund of healthcare-focused GP OrbiMed.
Qiming leads $21m round for Chinese cancer drug developer
China-based cancer drug developer Antengene Corporation has completed a $21 million Series A round of funding led by Qiming Venture Partners.